No approved drugs for fatty liver: could this diabetes medication be the answer?
NCT ID NCT06983171
Summary
This study is testing if a medication called semaglutide, given as a weekly injection for three years, can improve liver health in people with fatty liver disease linked to obesity and diabetes. It will involve 70 adults and closely monitor their liver condition, weight, and heart health. The goal is to see if this drug, already used for diabetes and weight loss, can help control a common liver disease that currently has no approved medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia
Conditions
Explore the condition pages connected to this study.